Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
OpenAlex – April 28, 2022
Source: OpenAlex
Summary
Despite psilocybin's captivating promise for severe depression, Daws et al. (2022) sparks skepticism within psychology regarding methodological challenges. In a trial with 59 participants, concerns arise about blinding efficacy; perhaps 75% of participants could identify their treatment. This epistemological hurdle complicates attributing outcomes solely to psilocybin's interaction with tryptophan pathways in brain disorders. Psychotherapists leveraging cognitive psychology insights for mental health research topics must critically evaluate the role of expectancy. True understanding in psychedelics and drug studies requires moving beyond simple psychoanalysis of subjective experience.
Abstract
Here we raise issues in Daws et al. (2022) published in Nature Medicine.